STX209 · program

Arbaclofen for Autism spectrum disorder

Phase 2ActiveAllos Pharma Inc.

Indications for STX209: Autism spectrum disorder · Phase 2 Multiple sclerosis · Phase 3 Fragile X syndrome · Phase 3

Arbaclofen, a selective GABA-B receptor agonist, for social function and core symptoms in autistic children and adolescents. The idea is that boosting GABA-B inhibition rebalances cortical excitation and inhibition. Seaside Therapeutics' Phase 2 (209AS208, NCT01288716; 150 participants aged 5-21) missed its primary endpoint (ABC Social Withdrawal/Lethargy) but improved clinician-rated CGI-Severity. Seaside stopped development in 2013, and its open-label extension was terminated.

Development timeline

Phase 2Feb 2009 – Dec 2026
  1. UpcomingClinicalTrials.gov estimated primary completion of AIMS-2-CT2 (NCT07655115), the arbaclofen shiftability biomarker study in autistic children and adolescents: December 2026.
  2. missedAIMS-2-TRIALS-CT1 (122 ITT, ages 5-17, 16 weeks): no significant effect on the primary Vineland Socialization endpoint or the prespecified key secondary outcomes. All secondary endpoints favoured arbaclofen, with significant improvements on SRS-2, AIM total, some ABC subscales and quality of life. Sleep problems were more frequent on arbaclofen (57.6% vs 34.9%).↗
  3. AIMS-2-CT2 (NCT07655115) starts: a single-dose crossover biomarker study followed by 10 weeks of open-label treatment. It is registered as Phase 3 but is not a confirmatory efficacy trial.
  4. Trial startedAIMS-2-CT2 arbaclofen biomarker study starts in autism
  5. FinancingAllos Pharma receives a non-dilutive Simons Foundation grant for arbaclofen in autism↗
  6. Licensing dealAllos Pharma acquires global rights to arbaclofen↗
  7. Allos Pharma announces worldwide exclusive rights to granted patents and clinical programs for arbaclofen in further indications, including autism spectrum disorder.↗
  8. Licensing dealAllos Pharma obtains worldwide rights to arbaclofen in autism spectrum disorder↗
  9. missedCanadian ARBA trial (POND network) of arbaclofen vs placebo for 16 weeks in autistic children and teens aged 5-17: the Vineland social primary outcome improved but not significantly vs placebo; parent ratings showed gains in some secondary measures.↗
  10. Academic development restarts: the Canadian ARBA trial (NCT03887676, Holland Bloorview / POND network) starts, followed by AIMS-2-TRIALS-CT1 (NCT03682978) on 2019-09-19.
  11. missedSeaside Phase 2 of arbaclofen in autism (150 participants aged 5-21): no difference from placebo on the primary ABC Social Withdrawal/Lethargy subscale; a prespecified secondary analysis showed improvement on CGI-Severity.↗
  12. Seaside open-label extension 209AS209 (NCT01706523) registered as terminated, with primary completion July 2013. Sponsor development of arbaclofen in autism stopped.
  13. Trial terminatedSeaside terminates the open-label extension of STX209 in autism
  14. Seaside starts the randomised, placebo-controlled Phase 2 209AS208 (NCT01288716; 150 participants aged 5-21). Primary endpoint: ABC Social Withdrawal/Lethargy.
  15. Seaside Therapeutics opens study 22003 (NCT00846547), an open-label, flexible-dose Phase 2 of STX209 in autism spectrum disorder.

Readouts

  • December 2026AnticipatedRegistry resultsNCT07655115

    ClinicalTrials.gov estimated primary completion of AIMS-2-CT2 (NCT07655115), the arbaclofen shiftability biomarker study in autistic children and adolescents: December 2026.

  • 2026-01-22ReportedFull resultsmissedNCT03682978

    AIMS-2-TRIALS-CT1 (122 ITT, ages 5-17, 16 weeks): no significant effect on the primary Vineland Socialization endpoint or the prespecified key secondary outcomes. All secondary endpoints favoured arbaclofen, with significant improvements on SRS-2, AIM total, some ABC subscales and quality of life. Sleep problems were more frequent on arbaclofen (57.6% vs 34.9%). ↗

  • 2023-05-05ReportedTopline datamissedNCT03887676

    Canadian ARBA trial (POND network) of arbaclofen vs placebo for 16 weeks in autistic children and teens aged 5-17: the Vineland social primary outcome improved but not significantly vs placebo; parent ratings showed gains in some secondary measures. ↗

  • 2016-10-17ReportedFull resultsmissedNCT01288716

    Seaside Phase 2 of arbaclofen in autism (150 participants aged 5-21): no difference from placebo on the primary ABC Social Withdrawal/Lethargy subscale; a prespecified secondary analysis showed improvement on CGI-Severity. ↗

Clinical trials in Autism spectrum disorder

NCT07655115AIMS-2-CT2Phase 3Recruitingn=103

A Follow-Up Shiftability Study of Arbaclofen With an Open-Label Extension for the Study of Biomarkers in Children and Adolescents With Autism Spectrum Disorders.

Started Nov 2025· Primary completion Dec 2026· 📍 5 sites across 2 countries (Spain, France)

NCT03682978AIMS2-CT-01Phase 2Completedn=124

A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders

Started Sept 2019· Primary completion Jan 2023· 📍 7 sites across 3 countries (United Kingdom, Spain, France)

NCT03887676ARB-05-2018Phase 2Completedn=90

A Randomized Placebo-controlled Trial of ARBaclofen vs. Placebo in the Treatment of Children and Adolescents With ASD

Started Mar 2019· Primary completion Aug 2023· 📍 4 sites across 1 country (Canada)

NCT01706523209AS209Phase 3Discontinuedn=165

An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of STX209 (Arbaclofen) in Subjects With Autism Spectrum Disorders

Started Nov 2011· Primary completion Jul 2013· 📍 25 sites across 1 country (United States)

NCT01288716209AS208Phase 2Completedn=150

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders

Started May 2011· Primary completion Aug 2012· 📍 24 sites across 1 country (United States)

NCT0084654722003Phase 2Completedn=32

An Open-Label, Flexible-Dose Evaluation of the Safety and Tolerability of STX209 for Treatment of Irritability in Subjects With Autism Spectrum Disorders

Started Feb 2009· Primary completion Jun 2010· 📍 8 sites across 1 country (United States)

Formulations

FormulationRouteRegimenPharmacokinetics
Arbaclofen oral (orally disintegrating) tablets, 5-20 mg BID-TID
AIMS-2-TRIALS-CT1 (NCT03682978): orally disintegrating tablets of 5, 10, 15 and 20 mg, flexibly titrated over 5 weeks and stratified by age. Ages 5-11 went from 5 mg BID up to 15 mg TID; ages 12-17 went from 5 mg QD up to 20 mg TID. Treatment lasted 16 weeks. The Canadian ARBA trial (NCT03887676) used the same orally disintegrating tablet strengths.
OralThree times daily—

Mechanism of action (compound-wide)

Selective orthosteric agonist of the GABA-B receptor, a Gi/o-coupled class C GPCR that works as a GABAB1/GABAB2 heterodimer; the agonist binds the GABAB1 subunit. Arbaclofen is the active R-enantiomer of baclofen, with 100- to 1000-fold greater GABA-B specificity than the S-enantiomer and about 5-fold greater potency than racemic baclofen. In the neurodevelopmental programs, the hypothesis is that GABA-B activation rebalances cortical excitation and inhibition and dampens excess glutamate release, which is implicated in fragile X syndrome (Fmr1 knockout models) and some autism. In spasticity, the effect comes from presynaptic inhibition of spinal reflexes, as with baclofen.

TargetActionAffinity
GABA-B receptorprimaryGABBR1Agonist—ⓘ

← Full STX209 compound page (identity, identifiers, all indications)

Sources

  1. Allos Pharma Acquires Global Rights to Arbaclofen, Reports Positive ASD Trial Results and Grant Award (2025-08-21, PR Newswire wire copy) — Allos Pharma Inc. (via The AI Journal)
  2. Allos Pharma Inc. Expands Intellectual Property Rights for Arbaclofen (2023-09-18, PR Newswire wire copy) — Allos Pharma Inc. (via BioSpace)
  3. NCT00846547 (22003) — Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders — ClinicalTrials.gov (U.S. National Library of Medicine)
  4. NCT01288716 (209AS208) — Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders — ClinicalTrials.gov (U.S. National Library of Medicine)
  5. NCT01706523 (209AS209) — Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders — ClinicalTrials.gov (U.S. National Library of Medicine)
  6. NCT03682978 (AIMS2-CT-01) — Arbaclofen in Children and Adolescents With ASD — ClinicalTrials.gov (U.S. National Library of Medicine)
  7. NCT03887676 (ARB-05-2018) — Arbaclofen vs. Placebo in the Treatment of Children and Adolescents With ASD (ARBA) — ClinicalTrials.gov (U.S. National Library of Medicine)
  8. NCT07655115 (AIMS-2-CT2) — Single Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th — ClinicalTrials.gov (U.S. National Library of Medicine)
  9. Okuda DT, et al. Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trial. Brain Commun 2022;4(6):fcac300 — Brain Communications (OUP) / PubMed
  10. Parellada M, et al. Efficacy, safety, and tolerability of arbaclofen in autistic children and adolescents, the AIMS-2-TRIALS-CT1: a randomized, double-blind, placebo-controlled phase II trial. EClinicalMedicine 2026;92:103760 — EClinicalMedicine (Elsevier) / PubMed
  11. Trials of arbaclofen for autism yield mixed results (2023-05-05) — The Transmitter (Simons Foundation)
  12. Veenstra-VanderWeele J, et al. Arbaclofen in children and adolescents with autism spectrum disorder: a randomized, controlled, phase 2 trial. Neuropsychopharmacology 2017;42(7):1390-1398 — Neuropsychopharmacology / PubMed